Elena Matsa
Overview
Explore the profile of Elena Matsa including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
2617
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hutschalik T, Ozgul O, Casini M, Szabo B, Peyronnet R, Bartulos O, et al.
Stem Cell Res Ther
. 2024 Sep;
15(1):280.
PMID: 39227896
Background: Atrial fibrillation has an estimated prevalence of 1.5-2%, making it the most common cardiac arrhythmia. The processes that cause and sustain the disease are still not completely understood. An...
2.
Guns P, Guth B, Braam S, Kosmidis G, Matsa E, Delaunois A, et al.
J Pharmacol Toxicol Methods
. 2020 Jun;
105:106889.
PMID: 32565326
Safety pharmacology is an essential part of drug development aiming to identify, evaluate and investigate undesirable pharmacodynamic properties of a drug primarily prior to clinical trials. In particular, cardiovascular adverse...
3.
Bozzi A, Sayed N, Matsa E, Sass G, Neofytou E, Clemons K, et al.
Stem Cell Reports
. 2019 May;
12(6):1232-1241.
PMID: 31105048
Chagas disease (ChD) is one of the most neglected tropical diseases, with cardiomyopathy being the main cause of death in Trypanosoma cruzi-infected patients. As the parasite actively replicates in cardiomyocytes...
4.
Lin Z, McGuire A, Burridge P, Matsa E, Lou H, Wu J, et al.
Microsyst Nanoeng
. 2019 May;
3:16080.
PMID: 31057850
The measurement of the electrophysiology of human pluripotent stem cell-derived cardiomyocytes is critical for their biomedical applications, from disease modeling to drug screening. Yet, a method that enables the high-throughput...
5.
Abilez O, Tzatzalos E, Yang H, Zhao M, Jung G, Zollner A, et al.
Stem Cells
. 2017 Nov;
36(2):265-277.
PMID: 29086457
The ability to differentiate human pluripotent stem cells (hPSCs) into cardiomyocytes (CMs) makes them an attractive source for repairing injured myocardium, disease modeling, and drug testing. Although current differentiation protocols...
6.
Kooreman N, de Almeida P, Stack J, Nelakanti R, Diecke S, Shao N, et al.
Cell Rep
. 2017 Aug;
20(8):1978-1990.
PMID: 28834758
There is growing interest in using embryonic stem cell (ESC) and induced pluripotent stem cell (iPSC) derivatives for tissue regeneration. However, an increased understanding of human immune responses to stem...
7.
Karakikes I, Termglinchan V, Cepeda D, Lee J, Diecke S, Hendel A, et al.
Circ Res
. 2017 Mar;
120(10):1561-1571.
PMID: 28246128
Rationale: Targeted genetic engineering using programmable nucleases such as transcription activator-like effector nucleases (TALENs) is a valuable tool for precise, site-specific genetic modification in the human genome. Objective: The emergence...
8.
Sharma A, Burridge P, McKeithan W, Serrano R, Shukla P, Sayed N, et al.
Sci Transl Med
. 2017 Feb;
9(377).
PMID: 28202772
Tyrosine kinase inhibitors (TKIs), despite their efficacy as anticancer therapeutics, are associated with cardiovascular side effects ranging from induced arrhythmias to heart failure. We used human induced pluripotent stem cell-derived...
9.
Matsa E, Burridge P, Yu K, Ahrens J, Termglinchan V, Wu H, et al.
Cell Stem Cell
. 2016 Aug;
19(3):311-25.
PMID: 27545504
Understanding individual susceptibility to drug-induced cardiotoxicity is key to improving patient safety and preventing drug attrition. Human induced pluripotent stem cells (hiPSCs) enable the study of pharmacological and toxicological responses...
10.